Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06767813 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

StatusRecruiting
PhasePhase 2
Started2024-03-19
View on ClinicalTrials.gov ↗

Amendment history

2025-09-15
Study Identification, Study Status, Study Design, Arms and Interventions, Contacts/Locations v1
Primary completion date2025-03→2026-11
Completion date2025-10→2026-11
Enrollment target50→80
Study sites2→7
Study arms1→2
InterventionsTQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules (Drug)→Albumin paclitaxel injection (Drug), Anlotinib capsules (Drug), Gemcitabine injection (Drug), TQB2868 injection (Drug)
2025-01-06
Original filing
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
Trial Details
NCT Number NCT06767813
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Pancreatic Neoplasms
Enrollment 80 participants
Start Date 2024-03-19
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-19